Jacob Pade Ramsøe Jacobsen is the CEO and Co-Founder of Evecxia Therapeutics, a company dedicated to treating CNS disorders by amplifying serotonin synthesis. A neuropharmacologist with a PhD from the University of Copenhagen, his career has spanned from research at Duke University to translating novel antidepressant concepts into FDA-approved drugs.
He is deeply committed to improving the lives of individuals with mental health disorders, particularly those with treatment-resistant depression and OCD. He is a vocal advocate for scientific accuracy in his field, publicly challenging research he deems flawed to prevent misinformation from impacting patient care.
Unique fact: He holds multiple patents for slow-release formulations of 5-hydroxytryptophan (5-HTP) as a novel approach to treating depression and other CNS disorders.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.